![]() Paxlovid is a medicine that has two different tablets one containing the active ingredient, nirmatrelvir (pink oval tablet) and the other containing the active ingredient, ritonavir, (white oval tablet). However, the National COVID-19 Clinical Evidence Taskforce recently updated its listing for Lagevrio to ‘ do not routinely use’ after determining that that there is now ‘high certainty evidence’ that it does not impact hospitalisation and/or mortality rates in multiply-vaccinated adults with one or more risk factors for disease progression. The most common side effects are diarrhoea, nausea and dizziness. There are no known drug interactions identified with Lagevrio based on the limited data that is currently available. If there are contraindications to Lagevrio then Paxlovid may be considered, however there are also many significant drug interactions to note with Paxlovid and GPs must make a special application to state and territory authorities to gain access. Likewise, breastfeeding is not recommended during treatment and for four days after the last dose of Lagevrio. Male patients who are sexually active with a partner who could become pregnant should use a reliable method of contraception during treatment and for three months after their last dose. Patients must use effective birth control while taking Lagevrio and for four days after stopping if there is a possibility of them getting pregnant. While not considered a high risk in residential aged care facilities (RACFs), it is especially important to note that Lagevrio is not recommended in pregnancy. Lagevrio can be taken with or without food, but patients should not open, break, or crush the capsules.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |